Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
USERS' SCORE
Good
Based on 83 Reviews
8.2
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Vitamin K2(as Menaquinone-7) (MK-7 ) (MenaQ7®)
100 mcg
**
Top Medical Research Studies
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
Most Useful Reviews
9
Vascular health
285 people found this helpful
Vitamin K2 contributes to vascular and heart health by preventing calcium from being incorrectly absorbed, thus lowering the risks associated with coronary heart disease.
Read More
7.5
Cardiovascular health
278 people found this helpful
This delicious vitamin K complex is essential for maintaining cardiovascular health. There are no side effects.
Read More
9
Inhibits coronary disease
269 people found this helpful
This product helps maintain vascular and heart health. Studies show that vitamin K2 can inhibit calcium deposition in vascular walls, thus reducing the risk of cardiovascular disease.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 5 Researches
7.4
- All Researches
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Read More
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
Read More
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
Read More
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
Read More
7
Atrial fibrillation treatment effectiveness confirmed
We explored how closely real-world patients with atrial fibrillation matched the results from major trials using apixaban and rivaroxaban compared to vitamin K antagonists. By tracking patients from the GARFIELD-AF registry, we observed that these real-life outcomes on stroke prevention, bleeding, and mortality closely mirrored those of the original trials. The study found that while the real-world patients had lower cardiovascular risks, the efficacy and safety of the treatments remained strong and comparable. This demonstrates that the findings from the ARISTOTLE and ROCKET AF trials are relevant in everyday clinical settings.
Read More
User Reviews
USERS' SCORE
Good
Based on 83 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
9
Vascular health
285 people found this helpful
Vitamin K2 contributes to vascular and heart health by preventing calcium from being incorrectly absorbed, thus lowering the risks associated with coronary heart disease.
Read More
7.5
Cardiovascular health
278 people found this helpful
This delicious vitamin K complex is essential for maintaining cardiovascular health. There are no side effects.
Read More
9
Inhibits coronary disease
269 people found this helpful
This product helps maintain vascular and heart health. Studies show that vitamin K2 can inhibit calcium deposition in vascular walls, thus reducing the risk of cardiovascular disease.
Read More
9
Calcium regulation
221 people found this helpful
Vitamin K2 is crucial for calcium absorption and blood clotting. It directs calcium to bones, benefiting the cardiovascular system and possibly combating cancer. Its positive impact on cardiovascular disease has been proven through research.
Read More
9
Essential for absorption
210 people found this helpful
K2 is vital for calcium absorption and blood clotting, ensuring cardiovascular system health by redirecting calcium effectively. Research shows its potential to combat cancer.
Read More
Frequently Asked Questions
9
Supports bone density
2 people found this helpful
My mother has been using NOW Foods MK-7 Vitamin K-2, and we've noticed impressive improvements in her bone density and cardiovascular health. It directs calcium to the bones, protecting her heart. The vegetarian capsules are easy to digest and non-GMO.
7.5
Reduces heart risks
4 people found this helpful
I take vitamin D3 at 5000 IU with K2 to prevent calcium build-up in vessels, reducing cardiovascular disease risks. MK-7 contributes to calcium metabolism, and I'm satisfied with the results after a two-month course.
9
Improved cardiovascular function
2 people found this helpful
I've taken Vitamin K2 for over four years and experienced benefits such as enhanced dental health and improved cardiovascular function. It also helped me avoid osteoporosis, especially at my age. Patience is key; it took about three years for me to notice these advantages. I recommend using it with Vitamin D3 for synergistic benefits on the immune system and overall health.
9
Vascular health
285 people found this helpful
Vitamin K2 contributes to vascular and heart health by preventing calcium from being incorrectly absorbed, thus lowering the risks associated with coronary heart disease.
9
Enhanced movement
31 people found this helpful
A necessary companion for vitamin D-3. I've noticed reduced ankle swelling and improved spirits within a week. It's remarkable how vitamins can enhance overall well-being.
9
Promotes arterial health
47 people found this helpful
Vitamin K2 (MK-7) supports bone and cardiovascular health. It promotes proper calcium exchange in blood vessels, essential for maintaining arterial health. I take it with vitamin D3 for better absorption and recommend it highly.
9
Supports cardiovascular health
140 people found this helpful
Vitamin K2 (MK-7), prescribed for postmenopausal women and men over 55, is effective at reducing the risk of cardiovascular disease. It aids calcium absorption and may mitigate the negative impact of statins that lower vitamin K levels in the blood. MK-7 also helps reduce arterial stiffness and calcium calcification. It's important to consider alternatives to vitamin K antagonists like warfarin for blood clot prevention. I recommend taking it every other day with vitamin D for optimal results.
9
Reduces mortality risk
14 people found this helpful
Vitamin K2 (MK-7) effectively reduces the risk of osteoporosis and cardiovascular disease. It plays a vital role in calcium absorption and interaction with vitamin D. Investing in your health through vitamins is worthwhile!
7.5
Enhances cardiovascular system
63 people found this helpful
I order this for my 65-year-old mother. She's taking vitamin D and MK-7 to support her cardiovascular system. It helps counteract the potential side effects of vitamin D.
7.5
Supports vascular health
5 people found this helpful
Vitamin K2 is essential for bone health and vital bodily functions. The MK-7 form can remain longer in the body, benefiting cardiovascular health by facilitating calcium metabolism. I take it alongside D3 5000, particularly important for calcium management.
9
Enhances calcium use
2 people found this helpful
Calcium strengthens bones but can risk cardiovascular disease if deposited incorrectly. Vitamin K draws calcium from the bloodstream to the bones, so combining it with vitamin D is beneficial. A daily dose of 100 mcg is sufficient for health.
9
Improved cardiovascular system
1 people found this helpful
This is a fantastic combination of essential vitamins D3 and K2, with perfect daily dosages. I purchased it for myself and my father, who has chronic kidney disease and is on dialysis. It has been recommended to help manage calcium and calcification processes, improving both cardiovascular health and bone strength. It's another quality product from Now Foods that I love.
9
Improves heart health
2 people found this helpful
NOW Foods MK-7 Vitamin K-2 has become integral to my daily supplements. Each 100 mcg capsule promotes stronger bones and heart health. I've observed positive changes in my bone density and overall cardiovascular wellbeing, confirming their high quality.
7
VKAs show limited effectiveness in AF
We evaluated the effectiveness of vitamin K antagonists (VKAs) in patients with both valvular and nonvalvular atrial fibrillation. Over an average follow-up of 17 months involving 1,350 patients, we found that the annual incidence of thromboembolic events and cardiovascular death was 4.4%. However, prior thromboembolism and bleeding, along with factors like kidney function and left atrial size, emerged as significant predictors of adverse clinical outcomes. Importantly, VKAs demonstrated limited benefits, as the overall findings highlighted more risk factors than significant treatment advantages.
7
Anticoagulant treatment effectiveness assessment
We explored the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation post-mitral valve transcatheter edge-to-edge repair (M-TEER). Our analysis included data from 206 patients, and we found that the incidence of serious events was similar between the two groups, indicating no significant benefit for either treatment. However, VKAs were linked to higher overall mortality. These findings suggest that while DOACs and VKAs may be similarly effective in preventing thromboembolic incidents, VKAs could pose greater risks for death.
7
We examined the effectiveness and safety of vitamin K antagonists (VKAs) in resolving left ventricular thrombosis in a group of 90 patients over 12 months.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
While we found that 70% experienced resolution of the thrombosis by the end of the study, the presence of low left ventricular ejection fraction and aneurysms negatively impacted outcomes.
Overall, the rate of complications, including strokes and major bleeding, remained low during the treatment period, indicating that VKAs can be a viable option, though some patients may face challenges in resolution.
9
Impact of renal function on anticoagulation
We explored how kidney function impacts the safety and effectiveness of different anticoagulant therapies in patients with atrial fibrillation. By analyzing data from the GLORIA-AF registry involving over 10,000 patients, we found that better kidney function was linked to lower risks of serious health events.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
Notably, those on non-vitamin K antagonist oral anticoagulants (NOACs) experienced significantly improved outcomes compared to those using vitamin K antagonists (VKAs). This suggests that NOACs are a safer choice for AF patients, especially for those with varying levels of kidney function.
References
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. doi:10.1007/s11739-025-03922-6
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. doi:10.36660/abc.20240147
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. doi:10.1007/s11239-025-03067-5
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. doi:10.1161/JAHA.124.038834
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002966
